Dr Low Jia Li is currently an Associate Consultant with the Department of Haematology-Oncology, National University Hospital (NUH).
Dr Low studied medicine at the Yong Loo Lin School of Medicine, National University of Singapore (NUS) and obtained her postgraduate qualifications from the Royal College of Physicians (UK). She subsequently completed postgraduate residency training in Internal Medicine and Medical Oncology at the National University Health System, Singapore and was the Chief Senior Resident of the Medical Oncology Programme from 2020-2021. Her areas of clinical and research interests include lung cancer, head and neck cancer, and geriatric oncology and has published in several scientific papers in respected peer-reviewed medical journals.
1. Low JL, SM Lim, JB Lee, et al. Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. Therapeutic Advances in Medical Oncology 15:175883592211461. Published 2023 Jan. DOI: 10.1177/17588359221146131
2. Low JL, Lim E, Bharwani L, et al. Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia. Ther Adv Med Oncol. 2022;14:17588359221139678. Published 2022 Dec 18. doi:10.1177/17588359221139678
3. Low JL, Huang Y, Sooi K, et al. Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank). Front Oncol. 2022;12:932212. Published 2022 Nov 17. doi:10.3389/fonc.2022.932212
4. Pang A, Jiali L, Ng A, et al. Use of the Cancer and Aging Research Group Predictive Model for Chemotherapy-Related Toxic Effects in a Multiethnic, Older Adult Asian Population. JAMA Netw Open. 2022;5(10):e2237196. Published 2022 Oct 3. doi:10.1001/jamanetworkopen.2022.37196
5. Low JL, Huang Y, Sooi K, et al. Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. Int J Cancer. 2021;149(1):169-176. doi:10.1002/ijc.33534
6. Low JL, Chong Q, Wang L, Cher GB, Soo RA. Different treatment efficacies and side effects of cytotoxic chemotherapy. J Thorac Dis. 2020;12(7):3785-3795. doi:10.21037/jtd.2019.08.63
7. Low JL, Walsh RJ, Ang Y, Chan G, Soo RA. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Ther Adv Med Oncol. 2019;11:1758835919870360. Published 2019 Aug 28. doi:10.1177/1758835919870360
